AU2020351138A1 - Anti-stem cell factor antibodies and methods of use thereof in renal disease - Google Patents

Anti-stem cell factor antibodies and methods of use thereof in renal disease Download PDF

Info

Publication number
AU2020351138A1
AU2020351138A1 AU2020351138A AU2020351138A AU2020351138A1 AU 2020351138 A1 AU2020351138 A1 AU 2020351138A1 AU 2020351138 A AU2020351138 A AU 2020351138A AU 2020351138 A AU2020351138 A AU 2020351138A AU 2020351138 A1 AU2020351138 A1 AU 2020351138A1
Authority
AU
Australia
Prior art keywords
seq
antibody
amino acid
antibodies
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020351138A
Other languages
English (en)
Inventor
Martin Phillips
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Insmed Inc
Original Assignee
Insmed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insmed Inc filed Critical Insmed Inc
Publication of AU2020351138A1 publication Critical patent/AU2020351138A1/en
Assigned to INSMED INCORPORATED reassignment INSMED INCORPORATED Request for Assignment Assignors: Opsidio, LLC
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020351138A 2019-09-16 2020-09-16 Anti-stem cell factor antibodies and methods of use thereof in renal disease Pending AU2020351138A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962900927P 2019-09-16 2019-09-16
US62/900,927 2019-09-16
PCT/US2020/050974 WO2021055409A1 (en) 2019-09-16 2020-09-16 Anti-stem cell factor antibodies and methods of use thereof in renal disease

Publications (1)

Publication Number Publication Date
AU2020351138A1 true AU2020351138A1 (en) 2022-03-31

Family

ID=74868426

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020351138A Pending AU2020351138A1 (en) 2019-09-16 2020-09-16 Anti-stem cell factor antibodies and methods of use thereof in renal disease
AU2020348295A Pending AU2020348295A1 (en) 2019-09-16 2020-09-16 Anti-stem cell factor antibodies and methods of use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020348295A Pending AU2020348295A1 (en) 2019-09-16 2020-09-16 Anti-stem cell factor antibodies and methods of use thereof

Country Status (28)

Country Link
US (6) US20220324957A1 (enExample)
EP (3) EP4650367A3 (enExample)
JP (4) JP7717687B2 (enExample)
KR (1) KR20220079561A (enExample)
CN (2) CN114729036B (enExample)
AR (1) AR119979A1 (enExample)
AU (2) AU2020351138A1 (enExample)
BR (1) BR112022004776A2 (enExample)
CA (2) CA3154648A1 (enExample)
CL (1) CL2022000633A1 (enExample)
CO (1) CO2022003661A2 (enExample)
DK (1) DK4031569T3 (enExample)
DO (1) DOP2022000058A (enExample)
EC (1) ECSP22022676A (enExample)
ES (1) ES3053942T3 (enExample)
FI (1) FI4031569T3 (enExample)
IL (1) IL291385A (enExample)
MX (1) MX2022003159A (enExample)
PE (1) PE20230090A1 (enExample)
PH (1) PH12022550647A1 (enExample)
PL (1) PL4031569T3 (enExample)
PT (1) PT4031569T (enExample)
SA (1) SA522431966B1 (enExample)
TW (1) TWI875812B (enExample)
UA (1) UA129546C2 (enExample)
UY (1) UY38883A (enExample)
WO (2) WO2021055408A1 (enExample)
ZA (1) ZA202203272B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217942A1 (en) 2018-05-11 2019-11-14 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
US20220324957A1 (en) 2019-09-16 2022-10-13 Opsidio, LLC Anti-stem cell factor antibodies and methods of use thereof in renal disease
KR20250167153A (ko) * 2023-03-03 2025-11-28 셀덱스 쎄라퓨틱스, 인크. 항-줄기 세포 인자(scf) 및 항-흉선 기질 림포포이에틴(tslp) 항체, 및 이중특이적 구축물
WO2026079764A1 (ko) * 2024-10-10 2026-04-16 아주대학교산학협력단 마우스 scf를 중화하는 항체 및 이의 용도

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US7144731B2 (en) * 1989-10-16 2006-12-05 Amgen Inc. SCF antibody compositions and methods of using the same
HUT62011A (en) * 1989-10-16 1993-03-29 Amgen Inc Process for producing factors influencing the functioning of stem cells
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US5911988A (en) 1995-04-28 1999-06-15 Bayer Corporation Method for treating asthma using SCF antibody
JP3583214B2 (ja) 1995-12-01 2004-11-04 株式会社ニチレイ ヒトｓｃｆに対するモノクローナル抗体
US20090087878A9 (en) 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
US6399857B1 (en) * 1999-09-22 2002-06-04 Paradigm Genetics, Inc. Modified nucleotide sequence encoding a LexA DNA binding domain optimized for arabidopsis species
AR037756A1 (es) * 2001-12-17 2004-12-01 Bayer Corp Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma.
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
DK2383295T3 (en) 2003-12-10 2015-06-15 Squibb & Sons Llc Ip-10 antibodies and uses thereof
RU2407752C2 (ru) 2004-04-29 2010-12-27 Оцука Фармасьютикал Ко., Лтд. Антитела к гликопротеину vi и способы продуцирования и использования этих антител
WO2006002064A2 (en) 2004-06-14 2006-01-05 Aerovance, Inc. Antibody inhibiting stem cell factor activity and use for treatment of asthma
US20080248050A1 (en) 2006-06-30 2008-10-09 Uchicago Argonne, Llc Meta-specific vaccine, method for treating patients immunized with meta-specific vaccine
WO2009127046A1 (en) 2008-04-14 2009-10-22 Proscan Rx Pharma Inc. Prostate specific membrane antigen antibodies and antigen binding fragments
KR20200023495A (ko) 2011-01-10 2020-03-04 더 리젠츠 오브 더 유니버시티 오브 미시간 줄기 세포 인자 억제제
KR101384360B1 (ko) 2012-05-04 2014-04-14 아주대학교산학협력단 Ｓｃｆ 또는 이의 수용체를 억제하는 물질을 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물
EP4063391A1 (en) 2012-07-25 2022-09-28 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
WO2015006554A1 (en) 2013-07-10 2015-01-15 The Regents Of The University Of Michigan Therapeutic antibodies and uses thereof
US10927153B1 (en) 2015-05-20 2021-02-23 University Of South Florida Synthetic plasmodium antigens, compositions, and uses thereof
EP3337827B1 (en) 2015-08-19 2026-07-08 Pfizer Inc. Tissue factor pathway inhibitor antibodies and uses thereof
KR20170022409A (ko) 2015-08-20 2017-03-02 주식회사 와이바이오로직스 Scf 특이적 항체
US11091559B2 (en) * 2015-08-27 2021-08-17 Celldex Therapeutics, Inc. Anti-ALK antibodies and methods for use thereof
MX2018007818A (es) 2015-12-22 2019-07-01 Abbvie Stemcentrx Llc Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.
TWI773693B (zh) 2016-10-05 2022-08-11 新加坡商細胞研究私人有限公司 從臍帶的羊膜分離間質幹細胞的方法、從臍帶的羊膜分離的間質幹細胞群以及用於從臍帶的羊膜分離間質幹細胞的細胞培養基
WO2019066093A1 (ko) 2017-09-26 2019-04-04 주식회사 와이바이오로직스 Scf 특이적 항체
WO2019088658A1 (ko) 2017-10-31 2019-05-09 주식회사 컴워스파마 Scf 및 갈렉틴-1을 표적으로 하는 이중표적항체 및 그 용도
KR102131898B1 (ko) 2017-10-31 2020-07-08 주식회사 노벨티노빌리티 Scf 및 갈렉틴-1을 표적으로 하는 이중표적항체 및 그 용도
CN120305401A (zh) 2018-10-19 2025-07-15 总医院公司 用于肝病的治疗的组合物和方法
US20220324957A1 (en) 2019-09-16 2022-10-13 Opsidio, LLC Anti-stem cell factor antibodies and methods of use thereof in renal disease
JP2024511027A (ja) 2021-03-17 2024-03-12 オプシディオ， エルエルシー 幹細胞因子抗体及びその使用方法

Also Published As

Publication number Publication date
US20240076367A1 (en) 2024-03-07
UY38883A (es) 2021-04-30
TW202124434A (zh) 2021-07-01
EP4031569A4 (en) 2023-10-18
JP2022548646A (ja) 2022-11-21
CA3154649A1 (en) 2021-03-25
EP4031176A4 (en) 2023-11-29
DOP2022000058A (es) 2022-08-31
UA129546C2 (uk) 2025-05-28
US20220340655A1 (en) 2022-10-27
DK4031569T3 (da) 2025-11-17
US20230019680A1 (en) 2023-01-19
CN118561997A (zh) 2024-08-30
PL4031569T3 (pl) 2026-02-16
FI4031569T3 (fi) 2025-11-14
MX2022003159A (es) 2022-04-07
US11939373B2 (en) 2024-03-26
ES3053942T3 (en) 2026-01-28
PH12022550647A1 (en) 2023-03-27
US20210079084A1 (en) 2021-03-18
TWI875812B (zh) 2025-03-11
EP4650367A2 (en) 2025-11-19
BR112022004776A2 (pt) 2022-06-21
SA522431966B1 (ar) 2025-05-18
JP7717687B2 (ja) 2025-08-04
WO2021055409A1 (en) 2021-03-25
JP2022547733A (ja) 2022-11-15
EP4031176A1 (en) 2022-07-27
PE20230090A1 (es) 2023-01-16
CL2022000633A1 (es) 2022-11-11
AU2020348295A1 (en) 2022-04-07
CO2022003661A2 (es) 2022-04-08
EP4031569A1 (en) 2022-07-27
AR119979A1 (es) 2022-01-26
WO2021055408A1 (en) 2021-03-25
ZA202203272B (en) 2022-12-21
EP4031569B1 (en) 2025-08-20
CN114729036A (zh) 2022-07-08
CA3154648A1 (en) 2021-03-25
US20260193336A1 (en) 2026-07-09
US12410246B2 (en) 2025-09-09
KR20220079561A (ko) 2022-06-13
JP7698635B2 (ja) 2025-06-25
TW202523696A (zh) 2025-06-16
ECSP22022676A (es) 2022-05-31
IL291385A (en) 2022-05-01
CN114729036B (zh) 2024-07-02
JP2025125563A (ja) 2025-08-27
PT4031569T (pt) 2025-11-12
JP2025165991A (ja) 2025-11-05
EP4650367A3 (en) 2026-03-04
US20220324957A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
US12410246B2 (en) Anti-stem cell factor antibodies and methods of blocking the interaction between SCF and c-Kit
CN113227135A (zh) 用于治疗癌症和其他疾病的对紧密连接蛋白18.2具有特异性的结合分子、其组合物和方法
JP2021508707A (ja) Ｐｄ−ｌ１に対する抗体及びそのバリアント
KR20230119693A (ko) 면역글로불린 경쇄 항체 및 이의 용도
US20240182556A1 (en) Stem cell factor antibodies and methods of use thereof
RU2844744C1 (ru) Антитела против фактора стволовых клеток и способы их применения
HK40078116B (en) Anti-stem cell factor antibodies and methods of use thereof
HK40078116A (en) Anti-stem cell factor antibodies and methods of use thereof
HK40112825A (en) Anti-stem cell factor antibodies and methods of use thereof
US8716235B2 (en) Method for inhibiting metastasis by using anti-CCL3 antibodies
AU2024331270A1 (en) Anti-tslp antibody constructs and uses thereof
WO2025195358A1 (zh) Pd-1结合蛋白及医药用途

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: INSMED INCORPORATED

Free format text: FORMER APPLICANT(S): OPSIDIO, LLC